WO2011153243A3 - Anti-angiogenesis therapy for treating gastric cancer - Google Patents

Anti-angiogenesis therapy for treating gastric cancer Download PDF

Info

Publication number
WO2011153243A3
WO2011153243A3 PCT/US2011/038765 US2011038765W WO2011153243A3 WO 2011153243 A3 WO2011153243 A3 WO 2011153243A3 US 2011038765 W US2011038765 W US 2011038765W WO 2011153243 A3 WO2011153243 A3 WO 2011153243A3
Authority
WO
WIPO (PCT)
Prior art keywords
gastric cancer
treating gastric
angiogenesis therapy
angiogenesis
therapy
Prior art date
Application number
PCT/US2011/038765
Other languages
French (fr)
Other versions
WO2011153243A2 (en
Inventor
Dimitrios Georg Chondros
Barbara Mueller
Eric Hedrick
Florin Sirzen
Original Assignee
Genentech, Inc.
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc., F. Hoffmann-La Roche Ag filed Critical Genentech, Inc.
Publication of WO2011153243A2 publication Critical patent/WO2011153243A2/en
Publication of WO2011153243A3 publication Critical patent/WO2011153243A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Abstract

Disclosed herein are methods and compositions comprising anti-VEGF antibodies for use in the treatment of gastric cancer.
PCT/US2011/038765 2010-06-02 2011-06-01 Anti-angiogenesis therapy for treating gastric cancer WO2011153243A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35079810P 2010-06-02 2010-06-02
US61/350,798 2010-06-02

Publications (2)

Publication Number Publication Date
WO2011153243A2 WO2011153243A2 (en) 2011-12-08
WO2011153243A3 true WO2011153243A3 (en) 2012-01-19

Family

ID=44627141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/038765 WO2011153243A2 (en) 2010-06-02 2011-06-01 Anti-angiogenesis therapy for treating gastric cancer

Country Status (1)

Country Link
WO (1) WO2011153243A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104292330B (en) * 2013-03-08 2017-07-14 上海赛伦生物技术股份有限公司 A kind of high human anti-VEGF antibody of stability and its application
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
TWI639430B (en) * 2016-08-27 2018-11-01 中國醫藥大學 Use of pharmaceutical composition for manufacturing drug of treating gastric cancer
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20090099344A1 (en) * 2003-07-28 2009-04-16 Fahrner Robert L Reducing protein a leaching during protein a affinity chromatography

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE164395T1 (en) 1990-12-03 1998-04-15 Genentech Inc METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ES2241710T3 (en) 1991-11-25 2005-11-01 Enzon, Inc. PROCEDURE TO PRODUCE MULTIVALENT PROTEINS FROM UNION TO ANTIGEN.
DE69333807T2 (en) 1992-02-06 2006-02-02 Chiron Corp., Emeryville MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
BR9207175A (en) 1992-10-28 1995-12-12 Genentech Inc Composition containing vascular endothelial cell growth factor antagonist polypeptide monoclonal antibody amino acid sequence and method of treatment of tumor in mammal
WO1994011026A2 (en) 1992-11-13 1994-05-26 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
PT1516628E (en) 1995-07-27 2013-09-24 Genentech Inc Stable isotonic lyophilized protein formulation
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
AU740738B2 (en) 1997-04-07 2001-11-15 Genentech Inc. Humanized antibodies and methods for forming humanized antibodies
TR199903123T2 (en) 1997-04-07 2000-05-22 Genentech, Inc. Anti-Vegf antikorlar�.
DE69830315T2 (en) 1997-06-24 2006-02-02 Genentech Inc., San Francisco GALACTOSYLATED GLYCOPROTEIN CONTAINING COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
ES2340112T3 (en) 1998-04-20 2010-05-28 Glycart Biotechnology Ag ANTIBODY GLICOSILATION ENGINEERING FOR THE IMPROVEMENT OF DEPENDENT CELLULAR CYTOTOXICITY OF ANTIBODIES.
WO2000042072A2 (en) 1999-01-15 2000-07-20 Genentech, Inc. Polypeptide variants with altered effector function
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
LT2857516T (en) 2000-04-11 2017-09-11 Genentech, Inc. Multivalent antibodies and uses therefor
EP2341060B1 (en) 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
WO2003035835A2 (en) 2001-10-25 2003-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
RU2005136988A (en) 2003-05-30 2006-06-10 Дженентек, Инк. (Us) ANTIBODY TREATMENT AGAINST VEGF
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20090099344A1 (en) * 2003-07-28 2009-04-16 Fahrner Robert L Reducing protein a leaching during protein a affinity chromatography

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"793 Salvage therapy with bevacizumab, capecitabin, and mitomycin C (BECAM) for patients with metastatic colorectal or gastric cancer refractory to 5-fluorouracil, oxaliplatin, irinotecan, and cetuximab", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 3, no. 2, 1 October 2005 (2005-10-01), pages 226, XP005132907, ISSN: 1359-6349 *
B. F. EL-RAYES ET AL: "A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers", ANNALS OF ONCOLOGY, vol. 21, no. 10, 23 March 2010 (2010-03-23), pages 1999 - 2004, XP055012999, ISSN: 0923-7534, DOI: 10.1093/annonc/mdq065 *
CATALANO V ET AL: "Gastric cancer", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 71, no. 2, 1 August 2009 (2009-08-01), pages 127 - 164, XP026251198, ISSN: 1040-8428, [retrieved on 20090220], DOI: 10.1016/J.CRITREVONC.2009.01.004 *
JAVLE MILIND ET AL: "Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, vol. 3, no. 1, 23 March 2010 (2010-03-23), pages 11, XP021083337, ISSN: 1756-8722, DOI: 10.1186/1756-8722-3-11 *
KELSEN D ET AL: "Analysis of survival with modified docetaxel, cisplatin, fluorouracil, and bevacizumab in patients with metastatic gastroesophageal adenocarcinoma: Results of a phase II clinical trial", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 27, 1 January 2009 (2009-01-01), pages 4512, XP009154355, ISSN: 0732-183X *
MORABITO A ET AL: "Systemic treatment of gastric cancer", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 70, no. 3, 1 June 2009 (2009-06-01), pages 216 - 234, XP026104335, ISSN: 1040-8428, [retrieved on 20081001], DOI: 10.1016/J.CRITREVONC.2008.08.005 *
NINOMIYA S ET AL: "Effect of Bevacizumab, a Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, on Peritoneal Metastasis of MNK-45P Human Gastric Cancer in Mice", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 154, no. 2, 15 June 2009 (2009-06-15), pages 196 - 202, XP026151213, ISSN: 0022-4804, [retrieved on 20080916], DOI: 10.1016/J.JSS.2008.08.017 *
SHAH MANISH A ET AL: "Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 20 NOV 2006 LNKD- PUBMED:17114652, vol. 24, no. 33, 20 November 2006 (2006-11-20), pages 5201 - 5206, XP009154389, ISSN: 1527-7755 *

Also Published As

Publication number Publication date
WO2011153243A2 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
IL276434A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
IL279330A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014031487A8 (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same
EP2714081A4 (en) Methods, compositions, and kits for the treatment of cancer
WO2013114367A8 (en) C10rf32 antibodies, and uses thereof for treatment of cancer
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
MX2011010955A (en) Adjuvant cancer therapy.
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
WO2012006634A3 (en) Prostate specific antigen (psa) peptide therapy
EP2651443A4 (en) Anti-ccl25 and anti-ccr9 antibodies for the prevention and treatment of cancer and cancer cell migration
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
EP2590712A4 (en) System and method for hyperthermic tumor treatment
WO2011153243A3 (en) Anti-angiogenesis therapy for treating gastric cancer
ME02932B (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP2635273A4 (en) Isoflavonoid compositions and methods for the treatment of cancer
EP2547368A4 (en) Methods and compositions for the treatment of cancer
WO2011133480A3 (en) Method of treating gastric cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11726014

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11726014

Country of ref document: EP

Kind code of ref document: A2